The views of older women towards mammographic screening: a qualitative and quantitative study

The views of older women towards mammographic screening: a qualitative and quantitative study
K Collins, M Winslow, M W Reed, S J Walters, T Robinson, J Madan, T Green, H Cocker and L Wyld
Br J Cancer 2010 102: 1461-1467

Link to Journal
 
There is a lack of knowledge about screening in older women. The majority felt that invitation to screening should be extended to the older age group regardless of age or health. The current under-utilised system of voluntary self-referral is not supported by older women

Cancer screening and preventative care among long-term cancer survivors in the United Kingdom

Cancer screening and preventative care among long-term cancer survivors in the United Kingdom
N F Khan, L Carpenter, E Watson and P W Rose
Br J Cancer 2010 102: 1085-1090

Link to Journal

Results: The cancer survivors’ cohort consisted of 18,612 breast, 5764 colorectal and 4868 prostate cancer survivors. Most cancer survivors receive cancer screening at the same levels as controls, except for breast cancer survivors who were less likely to receive a mammogram than controls (OR=0.78, 95% CI: 0.66–0.92). Long-term cancer survivors received comparable levels of influenza vaccinations and cholesterol tests, but breast (OR 0.81, 95% CI: 0.74–0.87) and prostate cancer survivors (OR=0.70, 95% CI: 0.57–0.87) were less likely to receive a blood pressure test. All survivors were more likely to receive bone densitometry.

Conclusion: The provision and uptake of preventive care in a primary care setting in the United Kingdom is comparable between the survivors of three common cancers and those who have not had cancer. However, long-term breast cancer survivors in this cohort were less likely to receive a mammogram

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
D G R Evans, A Moran, R Hartley, J Dawson, B Bulman, F Knox, A Howell and F Lalloo
Br J Cancer 2010 102:1091-1098

Link to Journal

Results: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46% in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P=0.05). Contralateral breast cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were ~2 per 1000. Altogether, 16 BRCA1, 9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold, respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a >90% probability having identifiable BRCA1/2 mutations

Conclusion: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged less than or equal to30 years to be tested

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced b

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
J Dose-Schwarz, R Tiling, S Avril-Sassen, S Mahner, A Lebeau, C Weber, M Schwaiger, F Jänicke, M Untch and N Avril
Br J Cancer 2010 102: 35-41

Link to Journal

FDG-PET does not provide an accurate assessment of residual tumour after primary chemotherapy of breast cancer. Magnetic resonance imaging offers the highest sensitivity, but all imaging modalities have distinct limitations in the assessment of residual tumour tissue when compared with histopathology

Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast

Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project
J Thomas, A Evans, J Macartney, S E Pinder, A Hanby, I Ellis, O Kearins, T Roberts, K Clements, G Lawrence and H Bishop on behalf of the Sloane Project Steering Group
Br J Cancer 2010 102: 285-293

Link to Journal

In a large series of screen-detected DCIS, we have shown that current approaches to preoperative imaging undersize the extent of disease in patients selected for BCS in up to 30% of cases, with the consequence of failed primary conservation surgery.
Further improvements in preoperative assessment should include detailed discussion between surgeon, radiologist and pathologist about radiological – pathological size correlation, particularly the extent of colocation of microcalcification and DCIS. Our data suggest that such discussion should be particularly targeted at intermediate and low-grade disease

Radiological staging in breast cancer: which asymptomatic patients to image and how

Radiological staging in breast cancer: which asymptomatic patients to image and how
T Barrett, D J Bowden, D C Greenberg, C H Brown, G C Wishart and P D Britton
Br J Cancer 2009 101: 1522-1528

Link to Journal

The findings from this Cambridge audit, prompted new local guidelines for staging asymptomatic breast cancer patients:

Only clinical stage III or IV patients require baseline investigation

The high specificity and convenience of computed tomography (chest, abdomen and pelvis including proximal femur) led us to recommend this as the investigation of choice in breast cancer patients requiring radiological staging

One-stop diagnostic breast clinics: how often are breast cancers missed?

One-stop diagnostic breast clinics: how often are breast cancers missed?
Britton, S W Duffy, R Sinnatamby, M G Wallis, S Barter, M Gaskarth, A O'Neill, C Caldas, J D Brenton, P Forouhi & G C Wishart
British Journal of Cancer (2009) 100, 1873 – 1878

Link to Journal

The aim of this study was to estimate the number of patients discharged from a symptomatic breast clinic who subsequently develop breast cancer and to determine how many of these cancers had been ‘missed’ at initial assessment. Over a 3-year period, 7004 patients were discharged with a nonmalignant diagnosis. Twenty-nine patients were subsequently diagnosed with breast cancer over the next 36 months. This equates to a symptomatic ‘interval’ cancer rate of 4.1 per 1000 women in the 36 months after initial assessment (0.9 per 1000 women within 12 months, 2.6 per 1000 women within 24 months). The lowest sensitivity of initial assessment was seen in patients of 40 – 49 years of age, and these patients present the greatest imaging and diagnostic challenge.

Following multidisciplinary review, a consensus was reached on whether a cancer had been missed or not. No delay occurred in 10 patients (35%) and probably no delay in 7 patients (24%). Possible delay occurred in three patients (10%) and definite delay in diagnosis (i.e., a ‘missed’ cancer) occurred in only nine patients (31%). The overall diagnostic accuracy of ‘triple’ assessment is 99.6% and the ‘missed’ cancer rate is 1.7 per 1000 women discharged